Human cxcl10 ip 10 quantikine elisa kit dip 100

Manufactured by R&D Systems

Sourced in United States

The Human CXCL10/IP-10 Quantikine ELISA Kit (DIP-100) is a quantitative sandwich enzyme immunoassay designed to measure human CXCL10/IP-10 levels in cell culture supernates, serum, and plasma.

Automatically generated - may contain errors

Lab products found in correlation

Human cxcl9 mig quantikine elisa kit, by R&D Systems (1 mentions) Human cxcl11 1 tac quantikine elisa kit, by R&D Systems (1 mentions)

2 protocols using human cxcl10 ip 10 quantikine elisa kit dip 100

Quantifying Secreted IP-10 in TNFα-Stimulated MCF-7 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Secreted IP-10 protein was quantified in supernatants of MCF-7 cells stimulated with TNFα using Human CXCL10/IP-10 Quantikine ELISA Kit (DIP-100, R&D Systems, Minneapolis, MN, USA), following the manufacturer’s instructions.

Kochumon S., Al-Sayyar A., Jacob T., Hasan A., Al-Mulla F., Sindhu S, & Ahmad R. (2021). TNF-α Increases IP-10 Expression in MCF-7 Breast Cancer Cells via Activation of the JNK/c-Jun Pathways. Biomolecules, 11(9), 1355.

+ Open protocol

+ Expand

Quantification of CXCL Chemokines in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cancer cell supernatants were obtained after in vitro culture under serum deprivation conditions. CXCL9, CXCL10 and CXCL11 were quantified using the human CXCL9/MIG Quantikine ELISA Kit (DCX900, R&D Systems, Minnesota, USA), human CXCL10/IP‐10 Quantikine ELISA Kit (DIP100, R&D Systems, Minnesota, USA) and human CXCL11/I‐TAC Quantikine ELISA Kit (DCX110, R&D Systems, Minnesota, USA), respectively, following the manufacturer's instructions.

Tang L., Zhang H., Zhou F., Wei Q., Du M., Wu J., Li C., Luo W., Zhou J., Wang X., Chen Z., Zhang Y., Huang Z., Wu Z., Wen Y., Jiang H., Liao D., Kou H., Xiong W., Mei H, & Hu Y. (2024). Targeting autophagy overcomes cancer‐intrinsic resistance to CAR‐T immunotherapy in B‐cell malignancies. Cancer Communications, 44(3), 408-432.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!